BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program
SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, QEDs oral FGFR1-3 inhibitor, in both urothelial carcinoma and cholangiocarcinoma (CCA).
- SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, QEDs oral FGFR1-3 inhibitor, in both urothelial carcinoma and cholangiocarcinoma (CCA).
- An analysis of response rates in patients with advanced/unresectable or metastatic urothelial carcinoma based on the amount of prior lines of treatment showed consistent response to infigratinib.
- All eight patients in the study with upper tract urothelial carcinoma (UTUC) received infigratinib as second-line or later therapy.
- Moreover, QED Therapeutics operates in a very competitive and rapidly changing environment in which new risks emerge from time to time.